Innovationen in der Therapie der Osteoporose

Osteoporose - Denosumab - Kathepsin K - Saracatinib - Sklerostin

osteoporosis - denosumab - cathepsin K - saracatinib - sclerostin

Literatur

• 1 Balemans W, Ebeling M, Patel N. et al . Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).  Hum Mol Genet. 2001;  10 537-543
• 2 Bekker P J, Holloway D L, Rasmussen A S, Murphy R, Martin S W, Leese P T, Holmes G B, Dunstan C R, DePaoli A M. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women.  J Bone Miner Res. 2005;  20 2275-2282
• 3 Bone H G, McClung M R, Roux C, Recker R R, Eisman J A, Verbruggen N, Hustad C M, DaSilva C, Santora A C, Ince B A. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.  J Bone Miner Res. 2010;  25 937-947
• 4 Brown J P, Prince R L, Deal C. et al . Comparison of the Effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial.  J Bone Miner Res. 2009;  24 153-161
• 5 Cummings S R, San Martin J, McClung M R. et al . FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.  N Engl J Med. 2009;  361 756-765
• 6 Diarra D, Stolina M, Polzer K. et al . Dickkopf-1 is a master regulator of joint remodeling.  Nat Med. 2007;  13 156-163
• 7 Hannon R A, Clack G, Rimmer M, Swaisland A, Lockton J A, Finkelman R D, Eastell R. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial.  J Bone Miner Res. 2010;  25 463-471
• 8 Heath D J, Chantry A D, Buckle C H, Coulton L, Shaughnessy J D Jr, Evans H R, Snowden J A, Stover D R, Vanderkerken K, Croucher P I. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.  J Bone Miner Res. 2009;  24 425-436
• 9 Hofbauer L C, Heufelder A E. Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases.  J Clin Endocrinol Metab. 2000;  85 2355-2363
• 10 Kimura S, Nakagawa T, Matsuo Y, Ishida Y, Okamoto Y, Hayashi M. JTT-305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats.  Eur J Pharmacol. 2011; ;  Jul 28. [Epub ahead of print]
• 11 Kramer I, Halleux C, Keller H, Pegurri M, Gooi J H, Weber P B, Feng J Q, Bonewald L F, Kneissel M. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis.  Mol Cell Biol. 2010;  30 3071-3085
• 12 Li X, Ominsky M S, Warmington K S. et al . Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.  J Bone Miner Res. 2009;  24 578-588
• 13 McClung M R, Lewiecki E M, Cohen S B. et al., AMG 162 Bone Loss Study Group . Denosumab in postmenopausal women with low bone mineral density.  N Engl J Med. 2006;  354 821-831
• 14 Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.  J Bone Miner Res. 2011;  26 19-26
• 15 Saftig P, Hunziker E, Everts V, Jones S, Boyde A, Wehmeyer O, Suter A, von Figura K. Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice.  Adv Exp Med Biol. 2000;  477 293-303